A Lower Viral Set Point but Little Immunological Impact After Early Treatment During Primary HIV Infection

The Primo-SHM trial, a multicenter randomized trial comparing no treatment with 24 or 60 weeks of combination antiretroviral therapy (cART) during primary human immunodeficiency virus (HIV) infection (PHI), recently demonstrated that temporary early cART lowered the viral set point and deferred the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Viral Immunol
Main Authors: Spits, Hilde B., Grijsen, Marlous L., Steingrover, Radjin, Nanlohy, Nening M., Kootstra, Neeltje, Borghans, José A.M., van Baarle, Debbie, Prins, Jan M., Schellens, Ingrid M.M.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2015
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390083/
https://ncbi.nlm.nih.gov/pubmed/25746670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/vim.2014.0094
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados